Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Retained Earnings (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Retained Earnings for 16 consecutive years, with -$5.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 106.92% to -$5.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.0 million, a 106.92% decrease, with the full-year FY2025 number at -$5.0 million, down 106.92% from a year prior.
  • Retained Earnings was -$5.0 million for Q4 2025 at Anika Therapeutics, roughly flat from -$4.9 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $231.4 million in Q3 2021 to a low of -$6.6 million in Q2 2022.
  • A 5-year average of $65.0 million and a median of -$5.3 million in 2024 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: skyrocketed 4468.79% in 2021, then crashed 106.92% in 2025.
  • Anika Therapeutics' Retained Earnings stood at -$5.7 million in 2021, then soared by 3785.19% to $210.7 million in 2022, then plummeted by 102.82% to -$5.9 million in 2023, then surged by 1305.91% to $71.7 million in 2024, then plummeted by 106.92% to -$5.0 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Retained Earnings are -$5.0 million (Q4 2025), -$4.9 million (Q3 2025), and $62.8 million (Q2 2025).